Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +46.93% | +72.54% | +44.34% | +61.17% | +64.95% |
| Gross Profit Growth | -0.48% | +57.55% | +29.60% | +54.88% | +96.99% |
| EBITDA Growth | -717.24% | +0.00% | +6455.27% | +0.00% | +0.00% |
| Operating Income Growth | -23925.93% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -135.22% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -133.33% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -134.29% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.77% | +2.85% | +3.43% | +2.62% | +2.60% |
| Weighted Average Shares Diluted Growth | -0.47% | +7.80% | +9.77% | +8.78% | +9.21% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +333.99% | +459.92% | +443.54% | +0.00% | +187.13% |
| Free Cash Flow Growth | +335.16% | +469.43% | +440.34% | +0.00% | +186.70% |
| Receivables Growth | +96.20% | +150.48% | +56.03% | +107.90% | -62.63% |
| Inventory Growth | -15.29% | -19.10% | +38.22% | +44.34% | +108.22% |
| Asset Growth | +10.30% | +15.33% | +21.89% | +28.28% | +31.54% |
| Book Value per Share Growth | -2.78% | +2.99% | +10.00% | +19.38% | +26.18% |
| Debt Growth | -19.60% | -18.35% | -14.36% | -8.28% | -3.63% |
| R&D Expense Growth | +77.27% | -26.18% | -21.53% | -7.36% | -1.40% |
| SG&A Expenses Growth | +10.33% | +12.53% | +10.54% | +5.83% | +40.06% |